These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ripretinib for the treatment of advanced gastrointestinal stromal tumor. Zalcberg JR Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
5. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. Keung EZ; Fairweather M; Raut CP Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287 [TBL] [Abstract][Full Text] [Related]
6. State of the Art in the Treatment of Gastrointestinal Stromal Tumors. Garlipp B; Bruns CJ Gastrointest Tumors; 2014 May; 1(4):221-36. PubMed ID: 26672673 [TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Croom KF; Perry CM Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228 [TBL] [Abstract][Full Text] [Related]
8. Current research and treatment for gastrointestinal stromal tumors. Lim KT; Tan KY World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140 [TBL] [Abstract][Full Text] [Related]
9. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Fairweather M; Balachandran VP; Li GZ; Bertagnolli MM; Antonescu C; Tap W; Singer S; DeMatteo RP; Raut CP Ann Surg; 2018 Aug; 268(2):296-302. PubMed ID: 28448384 [TBL] [Abstract][Full Text] [Related]
10. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751 [TBL] [Abstract][Full Text] [Related]
11. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. Na YS; Ryu MH; Yoo C; Lee JK; Park JM; Lee CW; Lee SY; Shin YK; Ku JL; Ahn SM; Kang YK Oncotarget; 2017 Sep; 8(44):76712-76721. PubMed ID: 29100343 [TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors. Blanke CD; Huse DM J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355 [TBL] [Abstract][Full Text] [Related]
13. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
14. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Lasota J; Miettinen M Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355 [TBL] [Abstract][Full Text] [Related]
16. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121 [TBL] [Abstract][Full Text] [Related]